Current role
Biotechnology · Healthcare
CEO, Board Member
2026-05-14–present
Emil D. Kakkis
Equibles does not estimate personal net worth.
Get an email with a short summary when Ultragenyx Pharmaceutical Inc. publishes a filing, an earnings call transcript or a press release.
Get RARE alertsAbout Emil D. Kakkis
Emil D. Kakkis is recorded as Board Member at Ultragenyx Pharmaceutical Inc. (RARE) since May 14, 2026 and CEO at Ultragenyx Pharmaceutical Inc. (RARE). The newest filing on record that lists Emil D. Kakkis as CEO at Ultragenyx Pharmaceutical Inc. (RARE) is dated March 27, 2026. The proxy statement of Ultragenyx Pharmaceutical Inc. reports total compensation of $11,405,535 for Emil D. Kakkis in fiscal 2025, including a base salary of $861,100. Disclosed compensation is on record for 9 fiscal years. Ultragenyx Pharmaceutical Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ultragenyx Pharmaceutical Inc. includes Emil Kakkis (CEO and Board Member), Howard Horn (CFO), Eric Crombez, M.D. (CTO) and 7 others.
Affiliation history
-
Current
2026-05-14–present
-
Current
Start not stated–present
Last confirmed March 27, 2026
Company network
Leadership on record at Ultragenyx Pharmaceutical Inc.
- Emil Kakkis CEO, Board Member
- Howard Horn CFO
- Eric Crombez, M.D. CTO
- Karah Parschauer General Counsel
- Amrit Ray, M.D. Board Member
- Clay B. Siegall Board Member
- Continuing Directors Board Member
- Corazon (Corsee) D. Sanders, Ph.D. Board Member
- Corsee Sanders, Ph.D. Board Member
- Daniel G. Welch Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Ultragenyx Pharmaceutical Inc. (RARE) | M.D., Ph.D. President and Chief Executive Officer | $861,100 | $11,405,535 |
| 2024 | Ultragenyx Pharmaceutical Inc. (RARE) | M.D., Ph.D. President and Chief Executive Officer | $856,008 | $13,717,687 |
| 2023 | Ultragenyx Pharmaceutical Inc. (RARE) | M.D., Ph.D. President and Chief Executive Officer | $823,692 | $13,077,993 |
| 2022 | Ultragenyx Pharmaceutical Inc. (RARE) | M.D., Ph.D. President and Chief Executive Officer | $796,154 | $12,140,330 |
| 2021 | Ultragenyx Pharmaceutical Inc. (RARE) | M.D., Ph.D. President and Chief Executive Officer | $768,846 | $9,522,738 |
| 2020 | Ultragenyx Pharmaceutical Inc. (RARE) | M.D., Ph.D. President and Chief Executive Officer | $759,231 | $5,144,220 |
| 2019 | Ultragenyx Pharmaceutical Inc. (RARE) | M.D., Ph.D. President and Chief Executive Officer | $714,000 | $6,553,142 |
| 2018 | Ultragenyx Pharmaceutical Inc. (RARE) | M.D., Ph.D. President and Chief Executive Officer | $679,952 | $4,812,800 |
| 2017 | Ultragenyx Pharmaceutical Inc. (RARE) | M.D., Ph.D. President and Chief Executive Officer | $638,115 | $6,684,899 |
Recent activity
No call appearances or filed executive changes recorded yet.